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Abstract In patients with haematological malignancies, the
bowel remains the main source of Escherichia coli blood-
stream infections. We present the clinical example of recurrent
bowel-blood translocations of E. coli with the unique viru-
lence characteristics in a 55-year-old male with the diagnosis
of acute myeloid leukaemia. The virulent factors profile of
examined strains confirmed that the co-existence of genes
papC, sfa, usp and cnf1, encoding virulence factors, predis-
poses E. coli to translocation from the gastrointestinal tract to
the vascular bed. The close cooperation between
haematologists and microbiologists is essential to improve
the outcome of patients colonised with highly pathogenic
strains.
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Background
Treatment of haematological malignancies with high-dose
chemotherapy leads to disruption of the mucosal epitheli-
um and prolonged agranulocytosis. Weakening of the im-
mune barriers makes the patients susceptible to life-
threatening bloodstream infections from their own micro-
biota (Cattaneo et al. 2014; Hamalainen et al. 2008; Olson
et al. 2014). The co-occurrence of genes papC, sfa, usp
and cnf1 encoding virulence factors (VFs) could predis-
pose Escherichia coli (E. coli) to translocation from the
gastrointestinal (GI) tract to the vascular bed (Krawczyk
et al. 2015). The aim of this study was to investigate
whether the unique profile of E. coli VFs determines the
ability to cross GI-blood barrier and to cause recurrent
episodes of bacteraemia. An answer to this question
would allow design of specific preventive strategies
aiming to reduce patients’ mortality due to E. coli blood-
stream infections.
Case report
We present the case of a 55-year-old male, admitted to the
Department of Haematology and Transplantology in
Gdańsk, with the diagnosis of acute myeloid leukaemia. He
was administered the induction chemotherapy according to
DAC protocol (Holowiecki et al. 2004). On the 4th day, a high
fever with C-reactive protein (CRP) 211 mg/L and
procalcitonin (PCT) 8.3 ng/mL was observed. Piperacillin
with tazobactam (Tazocin®) treatment was initiated and blood
cultures confirmed bacteremia with E. coli etiology, sensitive
to the administered antibiotic (Culture 1b). After 3 days his
temperature normalized. Due to the lack of complete remis-
sion (CR), he received a 2nd induction therapy — CLAG-M
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protocol (Wierzbowska et al. 2008), achieving the first CR
(CR1).
He relapsed after 6 months and was given the re-
induction therapy according to CLAG-M protocol that re-
sulted in CR2. During the next hospitalization he
underwent the first consolidation therapy — HAM proto-
col (Schlenk et al. 2005). On the 3rd day of agranulocyto-
sis, a high fever appeared with increased CRP (74 mg/L)
and PCT (17.3 ng/mL). Tazocin® was initially adminis-
tered, changed into meropenem after 2 days due to clinical
deterioration into septic shock, requiring the pressor ther-
apy. Blood cultures were positive with two isolates: E. coli
and S. epidermidis (Culture 2b). After 2 days he gradually
recovered.
He relapsed after 13 months and received re-induction che-
motherapy— FLAG-Ida protocol (Hashmi et al. 2005). From
the admission day he remained in agranulocytosis and devel-
oped febrile infection with CRP 17.9 mg/L and PCT 22.3 ng/
mL. Empiric therapy with cefoperazone plus sulbactam
(Sulperazon®) was given. Blood cultures were positive with
E. coli and E. faecalis isolates, both sensitive to Sulperazon®
(Culture 3b). His clinical status stabilized but his leukaemia
appeared to be chemo-resistant and he was disqualified from
the intensive treatment.
A few months later the relapse of bladder cancer was
diagnosed and transurethral resection of the bladder tu-
mour (TURBT) was performed. After the TURBT proce-
dure he became feverish and cefuroxime was prescribed by
the urologists. At that time he was permanently in agranu-
locytosis. After discontinuation of the antibiotic, a high
fever recurred with CRP 250 mg/l and PCT 41.2 ng/mL.
Cultures were taken and cefuroxime given again (culture
4b). Despite E. coli sensitivity to cefuroxime, there was no
clinical response. Therefore, antibiotic therapy was modi-
fied to ceftriaxone with amikacin, then changed into
Sulperazon®, prescribed and administered at the Daily
Haematological Unit. After 6 days of this therapy our pa-
tient was admitted to the hospital in critical clinical condi-
tion. Because of unfavourable prognosis the treatment was
not escalated and he died.
Material and methods
The collection of rectal swabs and stools was a prospective
routine procedure performed in high risk patients once a
week (for detection of the drug-resistant bacteria) and in
case of the febrile infection. E. coli as a part of the phys-
iological microbiome was isolated, identified and cryopre-
served from the same material to avoid additional
procedures in one patient. The selection of E. coli blood
isolates for the investigation was based on confirmed epi-
sodes of bacteraemia with E. coli, with the simultaneous
isolation of the microorganism from the stool or urine.
E. coli isolates were tested by DNA fingerprinting com-
bined with the PCR analysis of VFs. Genotyping of
E. coli by PCR melting profile and restriction endonucle-
ase analysis using pulsed-field gel electrophoresis were
carried out according to Krawczyk et al. (2006).
Determination of E. coli phylogenetic group was per-
formed with the use of the method by Clermont et al.
(2000). PCR screening of virulence genes was based on
methodology described by Krawczyk et al. (2015).
Results
The characteristics of examined strains are presented in
Table 1. The genotyping techniques confirmed that
E. coli isolates from blood shared the same genotype with
E. coli cultured from the patient’s bowel or urine. We per-
formed the analysis of 21 genes encoding VFs typical for
various E. coli pathotypes and established their relation-
ship with the phylogenetic group. No genes encoding
VFs characteristic for diarrhoeagenic E. coli (DEC) were
detected in PCR in tested blood isolates. The lack of these
VFs was also confirmed in serological tests. Isolates
belonged to pathogenic B2 (three episodes) and non-
pathogenic group B1 (one episode). The analysis of VFs
profiles for examined strains determined the presence of
four specific factors previously described, encoded by
papC, sfaD/E, cnf1, usp genes, and additional three factors,
encoded by agn43, hlyA, and iutA genes, also predisposing
to bowel colonization and translocation.
To assess the origin of the patient bacterial colonization,
the antibiotic resistance profile was performed using
sensitive/resistant categories together with MIC values.
The results showed sensitivity to the majority of tested
antibiotics with the primary resistance to fluoroquinolones
(Table 2). Due to a low frequency of multidrug-resistant
strains, we concluded that these bacteria were not of hos-
pital origin.
Conclusions
The case represents a frequently observed infectious pat-
tern of haematological patients with bacteraemia episodes
in the post-chemotherapy period of agranulocytosis. The
intestinal microbiota can cause life-threatening septic
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complications in this specific group of patients (Cattaneo
et al. 2014; Olson et al. 2014). The VFs of E.coli colonising
our patient and the clinical course with bacteraemia sharing
the same genotype profile confirmed that the co-existence
of genes encoding P fimbriae, S fimbriae, bacteriocin and
cytotoxic necrotizing factor seems to predispose E. coli to
translocation from the GI tract. This clinical example
strongly support the previously proposed concept of
bowel-blood translocation strains with the unique virulence
characteristics (Krawczyk et al. 2015). Since E.coli remains
the most frequent factor of bloodstream infections in pa-
tients with acute leukemia (Cattaneo et al. 2014), the pro-
phylactic use of antibiotics during the agranulocytosis pe-
riod, necessarily adjusted to the potential virulence and the
drug-resistance profile of colonising E.coli, would enable
to avoid the septic complications. This case justifies the
necessity of constant development in the diagnostic field
as well as a close cooperation between haematologists and
microbiologists to improve the outcome of patients with
haematological malignancies.








afa/dr fimG/H sfa papC hlyA usp cnf1 fyuA iutA ibeA iha focG ksp MTII agn43
Culture 1s stool A B2 + + + + − + + + + − − − + +
Culture 1b blood A B2 + + + + − + + + + − − − + +
Culture 2s stool B B1 + + + + − + + + + + − + − +
Culture 2b blood B B1 + + + + − + + + + + − + − +
Culture 3s stool C B2 − + + + + + + − + − + − − +
Culture 3b blood C B2 − + + + + + + − + − + − − +
Culture 4b blood C B2 − + + + + + + − + − + − − +
Culture 4u urine C B2 − + + + + + + − + − + − + +
a s- stool; b- blood; u- urine
b PCR melting profile
c afa/dr - Dr fimbriae (afa/draB–C), fimG/H - type 1 fimbriae (fimG/fimH), sfa - S fimbriae (sfaD/sfaE), papC - P fimbriae, hlyA - haemolysin, usp -
bacteriocin Usp, cnf1 - cytotoxic necrotizing factor, fyuA - yersiniabactin receptor, iutA - aerobactin receptor, ibeA - invasive protein, iha - enterobactin
(siderofor receptor and adherence factor), focG /H- F1C fimbriae, kspMTII - protein responsible for capsule formation, agn43 - adhesin 43 (biofilm
formation)





AM AMC TZP CXM CTX CAZ CRO FEP SCP IPM MEM AN GE NET CIP NOR SXT
Culture 1s stool R I S S S S S S S S S S S S R R R
Culture 1b blood R I S S S S S S S S S S S S R R R
Culture 2s stool R R S S S S S S S S S S S S R R R
Culture 2b blood R R S S S S S S S S S S S S R R R
Culture 3s stool R I S S S S S S S S S S S S R R R
Culture 3b blood R I S S S S S S S S S S S S R R R
Culture 4b blood R I S S S S S S S S S S S S R R R
Culture 4u urine R I S S S S S S S S S S S S R R R
AM: ampicillin; AMC: amoxycillin/clavulan acid; AN: amikacin; CAZ: ceftazidime: CIP: ciprofloxacin; CRO: ceftriaxone; CTX: cefotaxime; CXM:
cefuroxime; FEP: cefepime; GE: gentamicin; IPM: imipenem; MEM: meropenem NET: netelmicin; NOR: norfloxacin; SCP: cefoperazone/sulbactam
SXT: sulphamethoxazole/trimethoprim; TZP: piperacillin/tazobactam
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